Citation

Lee KH, Bahk WM, Lee SJ, Serretti A, Pae CU. Clin. Psychopharmacol. Neurosci. 2021; 19(1): 160-165.

Copyright

(Copyright © 2021, Korean College of Neuropsychopharmacology)

DOI

10.9758/CPN.2021.19.1.160

PMID

unavailable

Abstract

OBJECTIVE: We report the results of pharmacogenomics-based antidepressant treatment (PGXt) results in treating treatment- resistant major depressive disorder (TRD) patients in real practice.

METHODS: Nine patients were prescribed Neuropharmagen? for selection of antidepressants for individual patient and their clinical outcomes were followed.

RESULTS: After treatment by PGXt results from current antidepressants, substantial reduction of depressive symptoms was observed at some point and maintained during observation period in six patients.

CONCLUSION: Our case series potentially shows the clinical utility and benefit of PGXt for treatment of TRD patients. © 2021 Korean College of Neuropsychopharmacology. All rights reserved.

Language: en

Keywords

adult; human; female; male; case report; Treatment; insomnia; Depressive disorder; suicidal ideation; schizophrenia; loneliness; suicide attempt; major depression; disease severity; emotional disorder; hopelessness; fatigue; antidepressant agent; retrospective study; antisocial behavior; clinical article; doxepin; amfebutamone; amitriptyline; clomipramine; desipramine; fluoxetine; imipramine; mirtazapine; nortriptyline; paroxetine; serotonin uptake inhibitor; sertraline; xerostomia; fear; headache; middle aged; anxiety disorder; sleep disorder; mianserin; tremor; sweating; irritability; drug utilization; duloxetine; escitalopram; agitation; methylphenidate; treatment failure; remission; concentration loss; psychosocial withdrawal; paresthesia; aripiprazole; Montgomery Asberg Depression Rating Scale; Article; energy; Clinical outcome; young adult; pharmacogenetics; agomelatine; hand tremor; desvenlafaxine; adverse drug reaction; treatment resistant depression; sadness; clinical outcome; vortioxetine; Antidepressive agent; neuropharmagen; Treatment-resistance